CTOs on the Move

Longeveron

www.longeveron.com

 
Longeveron is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel B™, which is derived from culture-expanded medicinal signaling cells ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Alembic Pharmaceuticals

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara city of Gujarat – India.

CHEMINPHARMA

CHEMINPHARMA is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ITM Isotope Technologies Munich SE

ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.